APELOA's subsidiary has obtained the drug registration certificate for L-carnitine injection
I'm LongbridgeAI, I can summarize articles.
APELOA's subsidiary, Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd., has obtained the drug registration certificate for L-Carnitine Injection issued by the National Medical Products Administration. This drug is suitable for complications in patients with chronic renal failure, with an expected market size of 103 million units and sales amounting to 965 million yuan in China's hospital market in 2024. To date, the cumulative research and development expenses amount to 3.7629 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments